Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis (HILT-ESCOA)

5 octobre 2026 mis à jour par: Prof. Dr. Simin Hepgüler, Ege University

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial

This randomized, double-blind, sham-controlled clinical trial evaluated the effectiveness of high-intensity laser therapy (HILT) in patients with early-stage symptomatic knee osteoarthritis.

A total of 39 participants were randomly assigned to receive either HILT combined with a standardized home exercise program or sham laser therapy combined with the same exercise program. Laser or sham treatment was administered over 10 weekday sessions during a two-week period.

Participants were assessed at baseline, immediately after treatment, and at the three-month follow-up. Assessments included pain intensity, physical function, health-related quality of life, walking performance, knee range of motion, and muscle strength.

The aim was to determine whether adding HILT to exercise provides additional clinical benefits compared with sham laser therapy combined with exercise.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

39

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • İzmir
      • Izmir, İzmir, Turquie (Türkiye), 35100
        • Ege University Faculty of Medicine Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients presenting to the Physical Medicine and Rehabilitation outpatient clinics of Ege University Faculty of Medicine Hospital with knee pain lasting no longer than 6 months and a Visual Analog Scale (VAS) pain score of at least 4.
    2. Availability of bilateral weight-bearing knee radiographs in two views obtained within the preceding 6 months.
    3. Diagnosis of early symptomatic knee osteoarthritis according to the Italian Society of Rheumatology International Initiative (ESKOA) criteria.
    4. Ability to cooperate with the prescribed exercise program.
    5. Willingness to participate in the study and provision of informed consent.
    6. Age eligibility:
  • 40-49 years: Presence of at least one of the following risk factors for early symptomatic knee osteoarthritis.

  • 50-75 years: Eligible regardless of the presence of the listed risk factors.

Risk factors:

  • Body mass index (BMI) greater than 25 kg/m².
  • Family history of knee osteoarthritis.
  • Previous knee injury.
  • Lower-limb alignment abnormality.
  • Lower-limb length discrepancy.
  • Osteoarthritis at other anatomical sites.
  • Metabolic syndrome.
  • Difficulty initiating brisk walking or running after a period of inactivity.

Exclusion Criteria:

  1. Receipt of an intra-articular knee injection or physical therapy within the preceding 6 months, or use of natural health products such as glucosamine or chondroitin.

  2. History of knee surgery.

  3. Presence of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or gouty arthritis.

  4. History of trauma within the preceding 6 months.

  5. Fixed knee flexion deformity greater than 10 degrees or varus/valgus deformity greater than 15 degrees.

  6. Referred pain originating from the lumbar spine or hip.

  7. Neurological deficits affecting the lower extremities.

  8. Medical conditions that could prevent participation in the exercise program or completion of the study, including:

    • Myocardial infarction or cerebrovascular event within the preceding 3 months.
    • Congestive heart failure.
    • Severe chronic obstructive pulmonary disease.
    • History of myocardial ischemia during treadmill testing.
    • History of arterial or venous circulatory disorders.
  9. Presence of a cardiac pacemaker or metal implants.

  10. Pregnancy.

  11. History of malignancy, knee osteonecrosis, infectious disease, psychiatric illness, or bleeding diathesis.

  12. Epilepsy.

  13. Conditions impairing cooperation or communication, including language barriers, aphasia, marked affective disorders, or a history of severe psychiatric illness.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: HILT + Exercise

Participants received high-intensity laser therapy (HILT) combined with a standardized home exercise program. HILT was administered in 10 sessions over two consecutive weeks (five sessions per week). Participants also performed the prescribed home exercise program throughout the treatment period.

High-intensity laser therapy (HILT) was administered using a 1064-nm laser at a frequency of 20 Hz, with an energy density of 1530 mJ/cm² and a total energy of 3000 J per session. Treatment consisted of 10 sessions administered on consecutive weekdays over a two-week period. HILT was combined with a standardized home exercise program.

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Comparateur factice: Sham Laser + Exercise

Participants received sham laser therapy combined with the same standardized home exercise program as the experimental group. The sham procedure was administered without therapeutic laser energy in 10 sessions over two consecutive weeks (five sessions per week).

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Sham laser therapy was administered using the same treatment schedule and application procedure as the active HILT group, but without delivering therapeutic laser energy. Participants received 10 sham sessions over two consecutive weeks (five sessions per week), combined with the same standardized home exercise program.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Pain Intensity Assessed by Visual Analog Scale (VAS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Pain intensity was assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Symptoms and Physical Function Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee osteoarthritis-related symptoms and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), including pain, stiffness, and physical function subscales. Higher scores indicate greater symptom severity and functional impairment.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Functional Status Assessed by Health Assessment Questionnaire (HAQ)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional status and activities of daily living were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). Scores range from 0 to 3, with higher scores indicating greater disability and poorer functional status.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Physical Component Summary (PCS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Physical health-related quality of life was assessed using the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better physical health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Mental Component Summary (MCS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Mental health-related quality of life was assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Functional Exercise Capacity Assessed by 6-Minute Walk Test (6MWT)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional exercise capacity was assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes was recorded in meters. A greater walking distance indicates better functional exercise capacity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Range of Motion (ROM)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee range of motion was assessed using a goniometer. Active and passive knee range of motion were measured in degrees.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Lower Extremity Muscle Strength Assessed by Manual Muscle Testing (MMT)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Lower extremity muscle strength was assessed using manual muscle testing (MMT). Muscle strength was graded on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Paracetamol Use
Délai: Throughout the study period, from baseline to the 3-month follow-up

Paracetamol use was monitored using a patient diary to assess analgesic use during the study. Changes in paracetamol use were evaluated as an additional indicator of treatment effectiveness.

Throughout the study period, from baseline to the 3-month follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: A.Simin Hepgüler, MD, Ege University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 juin 2025

Achèvement primaire (Réel)

18 janvier 2026

Achèvement de l'étude (Réel)

18 janvier 2026

Dates d'inscription aux études

Première soumission

30 septembre 2026

Première soumission répondant aux critères de contrôle qualité

30 septembre 2026

Première publication (Réel)

6 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval.

Délai de partage IPD

De-identified individual participant data will be available upon reasonable request following publication of the manuscript.

Critères d'accès au partage IPD

De-identified individual participant data may be shared with qualified researchers upon reasonable request to the corresponding author (silaolmez@yahoo.com.tr), subject to ethical and institutional approval.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner